MedPath

Effect of Immune-enhancing Enteral Nutrition on Immunomodulation in Critically Ill Patients

Not Applicable
Completed
Conditions
Critical Illness
Interventions
Dietary Supplement: high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
Dietary Supplement: high-protein enteral nutrition of immune modulating nutrients without β-glucan
Dietary Supplement: standard enteral nutrition
Registration Number
NCT02569203
Lead Sponsor
Yonsei University
Brief Summary

To determine whether high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients (eg, ω-3 fatty acids and antioxidants) enriched with β-glucan stimulates immune functions compared with standard enteral nutrition (control: 20% of total calorie from protein) or high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients without β-glucan in critically ill patients.

Detailed Description

To determine whether high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients (eg, ω-3 fatty acids and antioxidants) enriched with β-glucan stimulates immune functions compared with standard enteral nutrition (control: 20% of total calorie from protein) or high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients without β-glucan in critically ill patients. In a randomized double-blind placebo-controlled study, 30 patients consumed 1 of 3 enteral nutrition: control, enteral nutrition of immune modulating nutrients enriched with β-glucan (250mg/L) or enteral nutrition of immune modulating nutrients without β-glucan. Enteral nutrition was initiated within 24 hours of ICU admission and continued during the ICU stay for a 7 days.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • ICU patients
Read More
Exclusion Criteria
  • ICU patients who could not receiving enteral nutrition
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
test group Ihigh-protein enteral nutrition of immune modulating nutrients enriched with β-glucanhigh-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
test group IIhigh-protein enteral nutrition of immune modulating nutrients without β-glucanhigh-protein enteral nutrition of immune modulating nutrients without β-glucan
control groupstandard enteral nutritionstandard enteral nutrition
Primary Outcome Measures
NameTimeMethod
Change from baseline NK cell activity at 7 daysat baseline and 7 days follow-up

NK cell activity (%)

Secondary Outcome Measures
NameTimeMethod
Change from baseline IL-12 at 7 daysat baseline and 7 days follow-up

IL-12 (pg/mL)

Change from baseline hs-CRP at 7 daysat baseline and 7 days follow-up

hs-CRP (mg/dL)

© Copyright 2025. All Rights Reserved by MedPath